G T Everson

Summary

Affiliation: University of Colorado Health Sciences Center
Country: USA

Publications

  1. ncbi Advances in management of polycystic liver disease
    Gregory T Everson
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Health Sciences Center, UCH AOP, PO Box 6510, 1635 N Ursula, B 154, Aurora, CO 80045, USA
    Expert Rev Gastroenterol Hepatol 2:563-76. 2008
  2. ncbi The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial
    G T Everson
    Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO 80262, USA
    Aliment Pharmacol Ther 27:798-809. 2008
  3. ncbi Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial
    Gregory T Everson
    Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO, USA
    Hepatology 44:1675-84. 2006
  4. ncbi Role of adult living donor liver transplantation in patients with hepatitis C
    Gregory T Everson
    Division of Gastroenterology/Hepatology, University of Colorado Health Sciences Center, Denver, CO 80202, USA
    Liver Transpl 9:S64-8. 2003
  5. ncbi Antiviral therapy for hepatitis C in the setting of liver transplantation
    Gregory T Everson
    Section of Hepatology, University of Colorado Health Sciences Center, 4200 East 9th Avenue, B 154, Denver, CO 80262, USA
    Curr Treat Options Gastroenterol 9:520-9. 2006
  6. ncbi Treatment of hepatitis C in the patient with decompensated cirrhosis
    Gregory T Everson
    Section of Hepatology, University of Colorado School of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Clin Gastroenterol Hepatol 3:S106-12. 2005
  7. ncbi Treatment of patients with hepatitis C virus on the waiting list
    Gregory T Everson
    University of Colorado School of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 9:S90-4. 2003
  8. ncbi Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy
    Gregory T Everson
    Section of Hepatology, Division of Gastroenterology and Hepatology, Department of Medicine, University of Colorado School of Medicine, 4200 East 9th Avenue, Denver, CO 80262, USA
    Hepatology 42:255-62. 2005
  9. ncbi Treatment of hepatitis C in patients who have decompensated cirrhosis
    Gregory T Everson
    University of Colorado School of Medicine, University of Colorado Health Sciences Center, 4200 East 9th Avenue, B 154 Denver, CO 80262, USA
    Clin Liver Dis 9:473-86, viii. 2005
  10. ncbi Management of cirrhosis due to chronic hepatitis C
    Gregory T Everson
    University of Colorado School of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Hepatol 42:S65-74. 2005

Detail Information

Publications73

  1. ncbi Advances in management of polycystic liver disease
    Gregory T Everson
    Division of Gastroenterology and Hepatology, Department of Medicine, University of Colorado Health Sciences Center, UCH AOP, PO Box 6510, 1635 N Ursula, B 154, Aurora, CO 80045, USA
    Expert Rev Gastroenterol Hepatol 2:563-76. 2008
    ..Recent research suggests that blockade of cyst secretion or inhibition of epithelial cells might be useful in halting progression of disease--these observations are discussed in this review...
  2. ncbi The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial
    G T Everson
    Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO 80262, USA
    Aliment Pharmacol Ther 27:798-809. 2008
    ..The spectrum of functional impairment in patients with compensated chronic hepatitis C is incompletely defined...
  3. ncbi Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial
    Gregory T Everson
    Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO, USA
    Hepatology 44:1675-84. 2006
    ..In conclusion, disease severity is a major independent determinant of rate of SVR in patients with advanced chronic hepatitis C. New strategies are needed to optimize antiviral therapy in these "difficult-to-cure" patients...
  4. ncbi Role of adult living donor liver transplantation in patients with hepatitis C
    Gregory T Everson
    Division of Gastroenterology/Hepatology, University of Colorado Health Sciences Center, Denver, CO 80202, USA
    Liver Transpl 9:S64-8. 2003
  5. ncbi Antiviral therapy for hepatitis C in the setting of liver transplantation
    Gregory T Everson
    Section of Hepatology, University of Colorado Health Sciences Center, 4200 East 9th Avenue, B 154, Denver, CO 80262, USA
    Curr Treat Options Gastroenterol 9:520-9. 2006
    ..These must be tested with urgency in the transplant setting. Retransplantation for progressive HCV disease is more controversial due to poor outcomes, graft shortage, and disease recurrence...
  6. ncbi Treatment of hepatitis C in the patient with decompensated cirrhosis
    Gregory T Everson
    Section of Hepatology, University of Colorado School of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Clin Gastroenterol Hepatol 3:S106-12. 2005
    ..Significant side effects and serious adverse events may complicate antiviral therapy in patients with advanced liver disease. Carefully controlled trials are needed to expand on these observations...
  7. ncbi Treatment of patients with hepatitis C virus on the waiting list
    Gregory T Everson
    University of Colorado School of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 9:S90-4. 2003
    ..5. Patients rendered hepatitis C virus RNA-negative pretransplantation may not experience posttransplantation recurrence...
  8. ncbi Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy
    Gregory T Everson
    Section of Hepatology, Division of Gastroenterology and Hepatology, Department of Medicine, University of Colorado School of Medicine, 4200 East 9th Avenue, Denver, CO 80262, USA
    Hepatology 42:255-62. 2005
    ..In conclusion, in a sizeable proportion of patients with advanced HCV, LADR may render blood free of HCV RNA, stabilize clinical course, and prevent posttransplantation recurrence...
  9. ncbi Treatment of hepatitis C in patients who have decompensated cirrhosis
    Gregory T Everson
    University of Colorado School of Medicine, University of Colorado Health Sciences Center, 4200 East 9th Avenue, B 154 Denver, CO 80262, USA
    Clin Liver Dis 9:473-86, viii. 2005
    ..This article discusses the current status of antiviral strategies in treating patients who have decompensated chronic hepatitis C before transplantation...
  10. ncbi Management of cirrhosis due to chronic hepatitis C
    Gregory T Everson
    University of Colorado School of Medicine, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    J Hepatol 42:S65-74. 2005
  11. ncbi Management of polycystic liver disease
    Gregory T Everson
    Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, 4200 East Ninth Avenue, B 154, Denver, CO 80262, USA
    Curr Gastroenterol Rep 7:19-25. 2005
    ..There is no effective medical therapy. Treatment options include cyst aspiration and sclerosis, open or laparoscopic cyst fenestration, hepatic resection, and liver transplantation...
  12. ncbi Polycystic disease of the liver
    Gregory T Everson
    Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO 80262, USA
    Hepatology 40:774-82. 2004
    ..There is no effective medical therapy. Interventional and surgical options include cyst aspiration and sclerosis, open or laparoscopic cyst fenestration, hepatic resection, and liver transplantation...
  13. ncbi Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt
    G T Everson
    Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Denver, CO, USA
    Aliment Pharmacol Ther 26:401-10. 2007
    ..Measurement of portal inflow and portal-systemic shunt using cholate clearances could be useful in monitoring patients with liver disease...
  14. ncbi Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis
    G T Everson
    Section of Hepatology, Department of Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
    Aliment Pharmacol Ther 27:542-51. 2008
    ..Patients with chronic hepatitis C virus and advanced fibrosis or cirrhosis are at risk for disease progression and hepatic decompensation...
  15. ncbi Is early steroid withdrawal after liver transplantation feasible with tacrolimus monotherapy?
    Gregory T Everson
    University of Colorado Health Sciences Center, UCH AOP Room 7085, 1635 N Ursula B 154, PO Box 6510, Aurora, CO 80045, USA
    Nat Clin Pract Gastroenterol Hepatol 5:194-5. 2008
  16. ncbi Increasing incidence and pretransplantation screening of hepatocellular carcinoma
    G T Everson
    Liver Transplantation, University of Colorado School of Medicine, Denver, CO 80262, USA
    Liver Transpl 6:S2-10. 2000
    ..This cost-benefit analysis is nearly identical to published rates for breast cancer screening ($30,000/QALY)...
  17. ncbi Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial
    G T Everson
    Section of Hepatology, Division of Gastroenterology and Hepatology, University of Colorado School of Medicine, Aurora, CO 80045, USA
    Aliment Pharmacol Ther 29:589-601. 2009
    ..The impact of virologic response on hepatic function has not been previously defined...
  18. ncbi Liver transplantation using sirolimus and minimal corticosteroids (3-day taper)
    J F Trotter
    Division of Gastroenterology, University of Colorado Health Sciences Center, Denver, CO, USA
    Liver Transpl 7:343-51. 2001
    ..Patient and graft survival rates were identical to those of historical controls. The findings in this report will serve as the basis for a formal trial evaluating the efficacy of sirolimus in liver transplantation...
  19. ncbi Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics
    G T Everson
    University of Colorado Health Sciences Center, Denver, CO, USA
    Hepatology 30:271-6. 1999
    ..We conclude that liver cirrhosis should not be a reason for excluding patients from therapy because both cirrhotic and fibrotic HCV patients benefit from IFN therapy not only by clearance of virus but by improvements in liver histology...
  20. ncbi Treatment of chronic hepatitis C in patients with decompensated cirrhosis
    Gregory T Everson
    University of Colorado School of Medicine, University of Colorado Health Sciences Center, Denver, CO, USA
    Rev Gastroenterol Disord 4:S31-8. 2004
    ..In the absence of a virologic cure, maintenance therapy with peginterferon may slow disease progression and reduce the rate of clinical decompensation...
  21. ncbi Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon
    Adrian M Di Bisceglie
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Ave, St Louis, MO 63110, USA
    N Engl J Med 359:2429-41. 2008
    ..Whether long-term antiviral therapy can prevent progressive liver disease in such patients remains uncertain...
  22. ncbi Impact of immunosuppressive therapy on recurrence of hepatitis C
    Gregory T Everson
    Hepatology, University of Colorado School of Medicine, Denver, CO 80262, USA
    Liver Transpl 8:S19-27. 2002
    ..Early reports suggest that disease activity may be more aggressive when these agents are constituents of the immunosuppressive regimen...
  23. ncbi Evaluation of 100 patients for living donor liver transplantation
    J F Trotter
    Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 6:290-5. 2000
    ..Recipient characteristics and donor availability may limit the widespread use of LDLT. However, careful application of LDLT to patients at greatest risk for dying on the waiting list may significantly reduce waiting list mortality...
  24. ncbi R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin
    Paul J Pockros
    Division of Gastroenterology and Hepatology, Scripps Clinic, La Jolla, CA 92037, USA
    Hepatology 48:385-97. 2008
    ..Dosing of R1626 was limited by neutropenia; a study of different dosages of R1626 in combination with peginterferon alfa-2a and ribavirin is underway...
  25. ncbi Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation
    Norah A Terrault
    Department of Medicine, Division of Gastroenterology, University of California at San Francisco, San Francisco, CA, USA
    Liver Transpl 13:122-9. 2007
    ..Important predictors of graft loss in HCV-infected patients were limited LDLT experience, pretransplant HCC, and higher MELD at transplantation...
  26. ncbi Right hepatic lobe donation for living donor liver transplantation: impact on donor quality of life
    J F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 7:485-93. 2001
    ....
  27. ncbi Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients
    Paul H Hayashi
    Division of Gastroenterology/Hepatology, University of Colorado Health Sciences Center, Denver 80262, USA
    Liver Transpl 9:737-40. 2003
    ..2 v 19.8 days; P =.01). In conclusion, MELD scores did not predict post-LDLT patient or graft survival at 1 year. However, higher MELD scores (> or =18) were associated with more hospital days during the 3-month post-LDLT period...
  28. ncbi Rapid, accurate, and sensitive fatty acid ethyl ester determination by gas chromatography-mass spectrometry
    Clark C Kulig
    Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, Denver, Colorado
    J Lab Clin Med 147:133-8. 2006
    ..In this article, we describe a novel method for rapid determination of the three major FAEEs found in human plasma...
  29. ncbi Should we treat patients with chronic hepatitis C on the waiting list?
    Gregory T Everson
    University of Colorado School of Medicine, University of Colorado Health Sciences Center, 4200 East 9th Avenue, B 154, Denver, CO 80262, USA
    J Hepatol 42:456-62. 2005
  30. ncbi De novo hepatocellular carcinoma in a patient with chronic hepatitis C 5 years after sustained virologic response to interferon/ribavirin therapy
    Kevin S Sieja
    Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, Denver, Colorado 80220, USA
    Dig Dis Sci 51:600-2. 2006
  31. ncbi Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial
    Adrian M Di Bisceglie
    Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saint Louis University School of Medicine, 3635 Vista Avenue, St Louis, MO 63110, USA
    J Hepatol 43:434-41. 2005
    ..We assessed serum AFP among patients with chronic hepatitis C and advanced fibrosis to establish predictors of AFP elevations and changes with antiviral therapy...
  32. ncbi The effects of desflurane and propofol on portosystemic pressure in patients with portal hypertension
    M Susan Mandell
    Department of Anesthesiology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Anesth Analg 97:1573-7. 2003
    ..This can cause errors in assessment of the success of medical therapy of portal hypertension. Propofol has less effect on the difference between the portal and systemic circulation...
  33. ncbi Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients
    James F Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, CO, USA
    Liver Transpl 8:212-8. 2002
    ....
  34. ncbi Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection
    Marcelo Kugelmas
    Divisions of Gastroenterology Hepatology, University of Colorado, Denver, CO 80262, USA
    Liver Transpl 9:1159-65. 2003
    ..0006). In conclusion, IS levels decreased significantly in patients responding favorably to anti-HCV therapy. This decrease in IS levels may have a key role in predisposing these patients to ACR...
  35. ncbi Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation
    Marcelo Kugelmas
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver 80262, USA
    Liver Transpl 9:727-32. 2003
    ..Length of corticosteroid use did not affect timing or risk of recurrence, and because it has been proven that early corticosteroid withdrawal after liver transplantation is beneficial, we continue to recommend this practice...
  36. ncbi Hepatocellular carcinoma extension into the right atrium
    Paul Hayashi
    Hepatology Division, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Liver Transpl 9:1225-6. 2003
  37. ncbi Adult-to-adult transplantation of the right hepatic lobe from a living donor
    James F Trotter
    Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, Denver 80262, USA
    N Engl J Med 346:1074-82. 2002
  38. ncbi Comprehensive cost comparison of adult-adult right hepatic lobe living-donor liver transplantation with cadaveric transplantation
    James F Trotter
    Division of Gastroenterology Hepatology, University of Colorado, Denver, CO 80262, USA
    Transplantation 75:473-6. 2003
    ..In this study, we compare the comprehensive cost of LDLT with that of cadaveric-liver transplantation...
  39. ncbi Combined liver-pancreas transplantation in a patient with primary sclerosing cholangitis and insulin-dependent diabetes mellitus
    J F Trotter
    Division of Gastroenterology, University of Colorado Health Sciences Center, Denver 80262, USA
    Transplantation 70:1469-71. 2000
    ..We report successful combined liver-pancreas transplantation in a patient with primary sclerosing cholangitis and insulin-dependent diabetes mellitus and review the literature on this topic...
  40. ncbi Immunosuppression in liver transplantation
    G T Everson
    Division of Gastroenterology and Hepatology and Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA
    Minerva Chir 58:725-40. 2003
    ..Ongoing advances in immunosuppressive and antiviral medications will allow tailoring of the immunosuppressive prescription, which undoubtedly will benefit current and future liver recipients...
  41. ncbi Impact of pretransplant diagnosis of hepatocellular carcinoma on cadveric liver allocation in the era of MELD
    Paul H Hayashi
    Hepatology Section, University of Colorado Health Sciences Center, Denver, CO, USA
    Liver Transpl 10:42-8. 2004
    ..More stringent HCC diagnostic criteria will be required to decrease the effect that misdiagnosis has on organ allocation...
  42. ncbi Polycystic liver: clinical characteristics of patients with isolated polycystic liver disease compared with patients with polycystic liver and autosomal dominant polycystic kidney disease
    Inge A Hoevenaren
    Department of Medicine, Division of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
    Liver Int 28:264-70. 2008
    ..The goal of this study was to compare the clinical features of patients with isolated polycystic liver disease (PCLD) with those of patients with polycystic liver and autosomal dominant polycystic kidney disease (ADPKD)...
  43. ncbi Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications
    Jeffrey C Dunkelberg
    Division of Gastroenterology/Hepatology, University of Colorado Health Sciences Center, Denver, CO, USA
    Liver Transpl 9:463-8. 2003
    ..The prevalence of wound and hepatic artery complications is not different in liver transplant recipients administered sirolimus as part of a primary immunosuppressive regimen compared with historic controls...
  44. ncbi Laparoscopic palliation of polycystic liver disease
    T N Robinson
    Department of Surgery, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, C313, Denver, CO 80262, USA
    Surg Endosc 19:130-2. 2005
    ..Symptomatic relief usually is temporary, and repeat surgery is required for recurring symptoms in half of the patients...
  45. ncbi Increased secondary bile acids in a choledochal cyst. Possible role in biliary metaplasia and carcinoma
    R M Reveille
    Department of Medicine, University of Colorado Health Sciences Center, Denver
    Gastroenterology 99:525-7. 1990
    ..Bile acids were fully conjugated. These data suggest that stasis of bile within choledochal cysts contributes to bacterial overgrowth and generation of unconjugated secondary bile acids...
  46. ncbi Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation
    Paul H Hayashi
    Division of Gastroenterology, University of Colorado Health Sciences Center, Denver, CO, USA
    Am J Transplant 4:782-7. 2004
    ..This balance is influenced greatly by the MELD system's determination of waiting times for HCC patients...
  47. ncbi HCV NS5B polymerase inhibitors
    James R Burton
    Department of Medicine, Division of Gastroenterology and Hepatology, University of Colorado, Denver, Aurora, CO 80045, USA
    Clin Liver Dis 13:453-65. 2009
    ..Whether these new drugs will have a role in the treatment of the difficult patient (non-responders, those co-infected with HIV, decompensated liver disease and liver transplant recipients) remains to be determined...
  48. ncbi Chronic albumin infusions to achieve diuresis in patients with ascites who are not candidates for transjugular intrahepatic portosystemic shunt (TIPS)
    J Trotter
    Division of Gastroenterology Hepatology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Dig Dis Sci 50:1356-60. 2005
    ....
  49. ncbi Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss
    T E Trouillot
    University of Colorado Health Sciences Center, Denver 80262, USA
    Am J Gastroenterol 96:1888-94. 2001
    ..Orlistat blocks these adverse changes in biliary lipid composition and maintains hepatobiliary function. We speculate that the risk of formation of gallstones during weight loss may actually be lowered with orlistat...
  50. ncbi Naturally acquired West Nile virus encephalomyelitis in transplant recipients: clinical, laboratory, diagnostic, and neuropathological features
    B K Kleinschmidt-Demasters
    Department of Pathology, University of Colorado Health Sciences Center, Denver, CO 80262, USA
    Arch Neurol 61:1210-20. 2004
    ....
  51. ncbi Atrial septal perforation from TIPS stent migration
    Paul H Hayashi
    Division of Gastroenterology, Department of Transplant Surgery, University of Colorado Health Sciences Center, Denver, Colorado, USA
    J Vasc Interv Radiol 15:629-32. 2004
    ..The case highlights a rare complication of TIPS and methods for treatment including transvenous removal, transvenous repair, and combined cardiotomy-liver transplantation surgery...
  52. ncbi Long-term management after liver transplantation: primary care physician versus hepatologist
    J Christie Heller
    Division of Gastroenterology and Hepatology, University of Colorado Health Sciences Center, Denver, CO, USA
    Liver Transpl 15:1330-5. 2009
    ..Future studies are needed to identify barriers to care in the treatment of metabolic complications post-transplant with the goal of improving long-term morbidity and mortality...
  53. ncbi Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C
    Chihiro Morishima
    Department of Laboratory Medicine, Virology Division, University of Washington, Seattle, WA, USA
    Hepatology 48:1412-9. 2008
    ..However, because patients with positive TMA results may achieve SVR, management decisions during therapy should not be based on a single positive TMA test result...
  54. ncbi Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial
    Leonard B Seeff
    Division of Digestive Diseases and Nutrition, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Hepatology 47:605-12. 2008
    ..Because its use among these HALT-C participants was self-motivated and uncontrolled, however, only a well-designed prospective study can determine whether silymarin provides benefit to persons with chronic hepatitis C...
  55. ncbi MELD: the answer or just more questions?
    Gregory T Everson
    Gastroenterology 124:251-4. 2003
  56. ncbi High relapse rate seen at week 72 for patients treated with R1626 combination therapy
    Paul Pockros
    Hepatology 48:1349-50. 2008
  57. ncbi Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C
    Karen L Lindsay
    Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, USA
    Clin Gastroenterol Hepatol 6:234-41. 2008
    ..Although viral kinetic profiles in treatment responders shed light on the mechanism of action of interferon and ribavirin, minimal information is available to explain why some patients experience little or no virologic suppression...
  58. ncbi Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C
    Vijayan Balan
    Mayo Clinic, Phoenix, AZ, USA
    Antivir Ther 11:901-8. 2006
    ..05). In conclusion, alb-IFN demonstrated robust induction of ISG that was consistent with the response associated with an IFN-alpha...
  59. ncbi Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 5:245-54. 2007
    ....
  60. ncbi Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis
    Robert J Fontana
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA
    Clin Gastroenterol Hepatol 2:183-97. 2004
  61. ncbi Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48210, USA
    Hepatology 42:282-92. 2005
    ..In conclusion, a model based on standard laboratory test results can be used to predict histological cirrhosis with a high degree of accuracy in 50% of patients with CHC...
  62. ncbi Possible autoimmune thrombocytopenia associated with pegylated interferon-alpha2a plus ribavarin treatment for hepatitis C
    Bruno C Medeiros
    J Clin Gastroenterol 38:84-6. 2004
  63. ncbi Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University, Richmond, 23298, USA
    Gastroenterology 126:1015-23; discussion 947. 2004
    ..This study evaluated the effectiveness of this treatment in patients who were nonresponders to previous interferon-based therapy...
  64. ncbi A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy
    Vijayan Balan
    Mayo Clinic, Phoenix, AZ, USA
    Antivir Ther 11:35-45. 2006
    ..These results support further clinical studies of albumin-IFN-alpha for the treatment of patients with chronic hepatitis C...
  65. ncbi HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial
    Chihiro Morishima
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98104, USA
    Hepatology 44:360-7. 2006
    ..In patients with negative PCR results during treatment, a single positive TMA test did not exclude SVR, although persistently positive tests did...
  66. ncbi Controversies in the management of hepatitis C virus infection after liver transplantation
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Health System, Richmond, VA 23298, USA
    Liver Transpl 9:1129-44. 2003
    ....
  67. ncbi Portal hypertensive gastropathy in chronic hepatitis C patients with bridging fibrosis and compensated cirrhosis: results from the HALT-C trial
    Robert J Fontana
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Am J Gastroenterol 101:983-92. 2006
    ..The clinical relevance of these findings will be further explored during the randomized phase of the HALT-C study...
  68. ncbi The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis
    Arun J Sanyal
    Division of Gastroenterology, Virginia Commonwealth University Health System, Richmond, Virginia, USA
    Gastrointest Endosc 64:855-64. 2006
    ..758). CONCLUSIONS: The risk of having varices increases with decreasing platelet counts, increasing bilirubin, and INR. The probability of having medium or large varices at platelet counts >150,000/mm(3) is negligible in this population...
  69. ncbi Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C
    Mitchell L Shiffman
    Hepatology Section, Virginia Commonwealth University Medical Center, Richmond, VA 23298, USA
    Gastroenterology 132:103-12. 2007
    ..However, prior studies did not assess the impact of reducing the dose of peginterferon independent of ribavirin or differentiate between dose reduction or interrupting or prematurely discontinuing treatment...
  70. ncbi Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders
    William M Lee
    Control Clin Trials 25:472-92. 2004
    ..The protocol changes enhanced enrollment while upholding the original goals of the study and its integrity...
  71. ncbi Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group
    Andrew D Bostom
    Department of Surgery, University of Minnesota, MMC-328 Mayo, Minneapolis 55455, USA
    Am J Transplant 2:491-500. 2002
  72. ncbi Everolimus and mTOR inhibitors in liver transplantation: opening the "box"
    Gregory T Everson
    Liver Transpl 12:1571-3. 2006
  73. ncbi Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure
    Achilles A Demetriou
    Liver Support Unit, Department of Surgery, Cedars Sinai Medical Center, 8700 Beverly Boulevard, Suite 8215, North Tower, Los Angeles, CA 90048, USA
    Ann Surg 239:660-7; discussion 667-70. 2004
    ..The safety and efficacy of the BAL were evaluated in a prospective, randomized, controlled, multicenter trial in patients with severe acute liver failure...